NSCLC STAGE IV

This study tests a drug called repotrectinib in 30 frail or elderly patients with advanced lung cancer that has a specific genetic change (ROS1). The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug by mouth, and doctors monitor t…

This study tests a new drug called M701, a bispecific antibody, in people with advanced non-small cell lung cancer that has caused fluid buildup in the chest (malignant pleural effusion). The drug is given directly into the chest cavity to target cancer cells and help control the…

This study looks at whether adding a precise radiation dose to liver tumors can make standard immunotherapy work better for people with stage IV non-small cell lung cancer. About 68 adults whose cancer has spread to the liver will either get standard drug therapy alone or standar…

This phase 3 trial tests whether adding an experimental drug (N-803) to standard chemotherapy (docetaxel) can help people with advanced non-small cell lung cancer whose disease has stopped responding to immunotherapy. About 507 participants will be randomly assigned to receive ei…

This study looks at how well the immunotherapy drug atezolizumab works as the first treatment for people with stage IV non-small cell lung cancer that has high PD-L1 levels (50% or more) and no targetable gene changes. Researchers will track 150 patients in Türkiye to see how lon…

This study tests a combination of two drugs (Sacituzumab Tirumotecan and Furmonertinib) in 25 people with advanced non-squamous non-small cell lung cancer that has an EGFR gene mutation and has stopped responding to standard treatments. The goal is to see if the combo can shrink …

This study tests whether adding pirfenidone to the immunotherapy drug atezolizumab can help shrink tumors and prevent treatment resistance in people with advanced or returning non-small cell lung cancer. About 25 adults with stage IV or recurrent NSCLC who have already tried at l…

This pilot study is testing a peptide vaccine designed to prevent or delay resistance in people with advanced ALK-positive lung cancer who are already on targeted therapy. The vaccine targets ALK protein mutations to boost the immune system. The study will enroll 12 participants …

This study tests whether adding a hormone therapy (leuprorelin) to an immunotherapy (sintilimab) can help older men with advanced lung cancer. The idea is that lowering sex hormones may rejuvenate the immune system, making the immunotherapy more effective. Eighty men aged 60 and …